How Much Does Wegovy Cost in Illinois in 2026?

Wegovy Retail Price in Illinois

The wholesale acquisition cost (WAC) for Wegovy set by Novo Nordisk is $1,349 per month, and that figure holds across Illinois retail pharmacies in 2026. This monthly price applies to the 2.4 mg maintenance dose, dispensed as a pack of four prefilled pens covering four weekly injections. Prices at individual pharmacies may vary by $20 to $50, but competitive discounting is minimal because supply remains constrained.

That sticker price places Wegovy among the most expensive chronic medications many Illinois patients will encounter. The Endocrine Society's 2024 obesity pharmacotherapy guideline notes that cost and insurance access are the primary barriers preventing eligible patients from starting anti-obesity medications. By comparison, older weight-loss drugs like phentermine cost $30 to $50 per month, though their efficacy is substantially lower.

Patients filling Wegovy prescriptions without any coverage should ask their pharmacist to run the prescription through discount aggregator platforms, which sometimes pull the effective price down to $1,100 to $1,250. The difference is modest, but for an annual spend exceeding $16,000, every reduction matters.

What STEP-1 and SELECT Showed About Wegovy's Value

Understanding what you are paying for helps contextualize the cost. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo. That magnitude of weight reduction was unprecedented for a pharmacotherapy-only intervention at the time of publication in 2021.

The cardiovascular evidence strengthened the case further. The SELECT trial (N=17,604), published in 2023, demonstrated a 20% reduction in major adverse cardiovascular events (MACE) among adults with overweight or obesity and established cardiovascular disease. Dr. A. Michael Lincoff, the trial's lead investigator, stated: "These findings indicate that semaglutide 2.4 mg reduces cardiovascular risk independent of diabetes status." That finding led to Wegovy's expanded FDA labeling in March 2024 to include cardiovascular risk reduction.

Illinois insurers have increasingly pointed to SELECT when justifying coverage expansions. A drug that prevents heart attacks and strokes carries a different cost-benefit profile than one that only reduces body weight.

Illinois Medicaid Coverage for Wegovy

Illinois Medicaid covers Wegovy with prior authorization (PA). The PA process requires the prescriber to document that the patient has a BMI ≥30, or ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber must also confirm that the patient has attempted lifestyle modifications (diet and exercise) for at least six months.

Processing times for Illinois Medicaid PA requests typically range from 48 hours to 14 days. Denials can be appealed, and the AMA's 2023 policy statement on anti-obesity medication access has been cited in successful appeals across multiple state Medicaid programs. If an initial PA is denied, Illinois patients should request a peer-to-peer review between their prescriber and the Medicaid medical director.

The Illinois Department of Healthcare and Family Services updated its preferred drug list in late 2025 to include semaglutide 2.4 mg, reflecting the CMS guidance on anti-obesity medication coverage that encouraged state Medicaid programs to evaluate GLP-1 receptor agonists for weight management. Patients on Medicaid managed care plans (such as Meridian, Molina, or Blue Cross Community) should verify coverage directly with their specific managed care organization, as formulary placement can differ from fee-for-service Medicaid.

Commercial Insurance Coverage in Illinois

Most large commercial insurers operating in Illinois now cover Wegovy, though the specifics vary. Blue Cross Blue Shield of Illinois, the state's largest commercial carrier, covers Wegovy on its specialty tier with PA requirements similar to those used by Medicaid. UnitedHealthcare, Aetna, and Cigna plans sold in Illinois also generally include Wegovy, but employer-sponsored plans can opt out of obesity drug coverage entirely.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends that insurers cover FDA-approved anti-obesity medications when prescribed according to labeling. That recommendation has increased pressure on Illinois employers to include these medications in their pharmacy benefits.

Patients should check three things before filling: (1) whether Wegovy is on their plan's formulary, (2) what tier it sits on, and (3) whether the plan imposes step therapy requiring a trial of a cheaper agent first. Some plans require patients to try orlistat or phentermine-topiramate before approving Wegovy. The STEP-8 trial showed semaglutide 2.4 mg produced significantly greater weight loss than liraglutide 3.0 mg (15.8% vs. 6.4% at 68 weeks), which can support appeals against step therapy requirements that mandate liraglutide first.

The Novo Nordisk Savings Card in Illinois

Novo Nordisk offers a manufacturer savings card that reduces Wegovy copays for commercially insured patients. Eligible patients pay as little as $0 per fill for up to 13 fills. The card does not apply to government insurance (Medicaid, Medicare, Tricare, VA).

To qualify, an Illinois patient must have commercial insurance that covers Wegovy and a valid prescription. Patients can enroll online through the manufacturer's patient support program. The savings card covers the difference between the patient's copay and $0, up to a maximum monthly benefit.

One critical detail: the savings card resets annually. Patients who start Wegovy mid-year will use fewer of their 13 fills before the program resets on January 1. Timing the start of therapy to maximize savings card coverage is a practical consideration Illinois patients should discuss with their prescriber.

For patients whose commercial plan does not cover Wegovy at all, Novo Nordisk operates a separate patient assistance program for households earning ≤400% of the federal poverty level. This program provides Wegovy at no cost to qualifying patients. Application requires income documentation and a prescription.

Compounded Semaglutide 2.4 mg in Illinois

Compounded semaglutide 2.4 mg is available from licensed 503A compounding pharmacies in Illinois at approximately $199 per month. That is 85% less than brand-name Wegovy.

The legal basis: Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications based on individual patient prescriptions when the prescriber determines a clinical need. In Illinois, the Illinois Department of Financial and Professional Regulation licenses these pharmacies, and semaglutide compounding is permitted when the pharmacy sources its active pharmaceutical ingredient from an FDA-registered facility.

The FDA has taken an active role in regulating compounded semaglutide, and the regulatory environment has shifted repeatedly since 2023. Patients considering this route should verify that their pharmacy holds a current 503A license, uses semaglutide base (not salt forms the FDA has flagged), and provides certificates of analysis for potency and sterility. The FDA's 2024 enforcement actions targeted pharmacies using semaglutide sodium, a salt form the agency considers a different active ingredient not covered by 503A provisions.

Dr. Caroline Apovian, a professor of medicine at Harvard Medical School, noted in a 2023 commentary: "Compounded GLP-1 agonists fill an access gap, but patients must understand they are not FDA-approved products and lack the manufacturing oversight of branded drugs" (JAMA, 2023).

Wegovy via Telehealth in Illinois

Illinois permits telehealth prescribing of Wegovy. The Illinois Telehealth Act allows licensed physicians and advanced practice providers to prescribe controlled and non-controlled medications following a real-time audio-video encounter. Since semaglutide is not a controlled substance, telehealth prescribing carries no additional scheduling restrictions.

Telehealth platforms operating in Illinois typically charge $99 to $199 for an initial weight-management consultation, with follow-up visits at $49 to $99 every one to three months. Some platforms bundle the consultation fee with the cost of compounded semaglutide, offering packages in the $250 to $399 per month range. Patients should confirm that the prescribing clinician holds an active Illinois medical license and that the platform ships from a pharmacy licensed in Illinois.

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy supports telemedicine delivery of anti-obesity medications when accompanied by appropriate monitoring, including periodic assessment of heart rate, blood pressure, and adverse effects such as pancreatitis and gallbladder disease, which are noted on the Wegovy label.

Cost Comparison: Brand vs. Compounded vs. With Insurance

Understanding the true out-of-pocket range helps Illinois patients pick the most realistic path. The table below reflects 2026 pricing.

Brand Wegovy, no insurance: $1,349/month ($16,188/year). This is the full retail scenario. Few patients sustain this long-term without assistance.

Brand Wegovy, commercial insurance with savings card: $0 to $25/month for up to 13 fills. After the savings card expires, copays revert to the plan's specialty tier, which typically runs $150 to $300/month depending on plan design.

Brand Wegovy, Illinois Medicaid: $0 to $3 copay after PA approval, per Illinois Medicaid copay schedules.

Compounded semaglutide 2.4 mg (503A pharmacy): Approximately $199/month ($2,388/year). Not covered by insurance. The FDA requires 503A pharmacies to compound based on individual prescriptions, so no bulk discount structures apply.

For a patient planning 12 months of therapy, the annual cost difference between brand Wegovy without insurance ($16,188) and compounded semaglutide ($2,388) is $13,800. That gap explains why compounding demand has surged, with one 2024 analysis estimating that 30% of GLP-1 prescriptions were being filled through compounding pharmacies.

Side Effects and Monitoring Costs to Factor In

The price of the drug itself is not the entire cost. Patients should budget for monitoring and management of adverse effects. In STEP-1, the most common adverse events were gastrointestinal: nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%). Most GI effects were mild to moderate and peaked during dose escalation.

Rarer but serious risks include acute pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (the latter observed in rodent studies, with no confirmed human signal to date). The FDA label carries a boxed warning regarding thyroid C-cell tumors. Illinois patients should expect their prescriber to order baseline and periodic labs including lipase, amylase, and thyroid function tests, adding $50 to $150 per lab draw depending on insurance.

The five-week dose-escalation schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg maintenance) means that patients fill lower-dose pens during months one through four. The cost per pen pack remains the same regardless of dose strength, so patients pay the same $1,349 during escalation as they do at maintenance.

How to Minimize Wegovy Cost in Illinois

A practical sequence for Illinois patients seeking the lowest possible cost:

Step 1. Confirm insurance coverage. Call the number on the back of your insurance card and ask: "Is semaglutide 2.4 mg (Wegovy) on formulary, and what tier?" If covered, ask about PA requirements and step therapy.

Step 2. Apply for the Novo Nordisk savings card before your first fill. Activation takes less than 10 minutes online.

Step 3. If your plan denies coverage, file an appeal citing the SELECT cardiovascular outcome data and the AACE 2023 obesity treatment algorithm. Ask your prescriber to do a peer-to-peer review.

Step 4. If you lack commercial insurance or face persistent denials, evaluate compounded semaglutide from a 503A-licensed Illinois pharmacy. Verify the pharmacy's license through the Illinois DFPR database.

Step 5. If household income is ≤400% FPL, apply for Novo Nordisk's patient assistance program for $0 brand Wegovy.

Patients on Illinois Medicaid should start with their managed care plan's PA process, as approval rates have risen since the SELECT data publication. The median PA turnaround in Illinois managed Medicaid is currently seven business days.